FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

John Radford

Research Profile

Procedures

Disorders

Chemicals & Drugs

Concepts & Ideas

Co-author Network

Publications

TOP 3
Khimara Naidoo; Vanessa Clay; Judith A Hoyland; Ric Swindell; Kim Linton; Timothy Illidge; John A Radford; Richard J Byers
YY1 expression predicts favourable outcome in follicular lymphoma.
Graham M Mead; Sharon L Barrans; Wendi Qian; Jan Walewski; John A Radford; Max Wolf; Simon M Clawson; Sally P Stenning; Claire L Yule; Andrew S Jack
A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial).
Andrew R Clamp; W D J Ryder; S Bhattacharya; R Pettengell; John A Radford
Patterns of mortality after prolonged follow-up of a randomised controlled trial using granulocyte colony-stimulating factor to maintain chemotherapy dose intensity in non-Hodgkin's lymphoma.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of John Radford (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Khimara Naidoo; Vanessa Clay; Judith A Hoyland; Ric Swindell; Kim Linton; Timothy Illidge; John A Radford; Richard J Byers
YY1 expression predicts favourable outcome in follicular lymphoma.
Journal of clinical pathology 2011;64(2):125-9.
2008: Graham M Mead; Sharon L Barrans; Wendi Qian; Jan Walewski; John A Radford; Max Wolf; Simon M Clawson; Sally P Stenning; Claire L Yule; Andrew S Jack
A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial).
Blood 2008;112(6):2248-60.
2008: Andrew R Clamp; W D J Ryder; S Bhattacharya; R Pettengell; John A Radford
Patterns of mortality after prolonged follow-up of a randomised controlled trial using granulocyte colony-stimulating factor to maintain chemotherapy dose intensity in non-Hodgkin's lymphoma.
British journal of cancer 2008;99(2):253-8.
2007: Ebrahim Sakhinia; Caroline Glennie; Judith A Hoyland; Lia P Menasce; Gerard Brady; Crispin Miller; John A Radford; Richard Byers
Clinical quantitation of diagnostic and predictive gene expression levels in follicular and diffuse large B-cell lymphoma by RT-PCR gene expression profiling.
Blood 2007;109(9):3922-8.
2007: Anthony J Swerdlow; Craig D Higgins; Paul Smith; David Cunningham; Barry W Hancock; Alan Horwich; Peter J Hoskin; Andrew Lister; John A Radford; Ama Z S Rohatiner; David C Linch
Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study.
Journal of the National Cancer Institute 2007;99(3):206-14.
2006: Peter WM Johnson; John A Radford; Michael H Cullen; Matthew R Sydes; Sally P Stenning; Barry W Hancock
Comparison of outcomes in studies of advanced Hodgkin's lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(20):3309; author reply 3309-10.
2005: Peter WM Johnson; John A Radford; Michael H Cullen; Matthew R Sydes; Jan Walewski; Andrew S Jack; Kenneth A MacLennan; Sally P Stenning; Simon Clawson; Paul Smith; David Ryder; Barry W Hancock
Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(36):9208-18.
2005: Mark S Kaminski; John A Radford; Stephanie A Gregory; John P Leonard; Susan J Knox; Stewart Kroll; Richard L Wahl
Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(31):7985-93.
2005: John M Bennett; Mark S Kaminski; John P Leonard; Julie M Vose; Andrew D Zelenetz; Susan J Knox; Sandra Horning; Oliver W Press; John A Radford; Stewart M Kroll; Robert L Capizzi
Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab.
Blood 2005;105(12):4576-82.
2005: Eleanor J Cheadle; David Gilham; Fiona C Thistlethwaite; John A Radford; Robert E Hawkins
Killing of non-Hodgkin lymphoma cells by autologous CD19 engineered T cells.
British journal of haematology 2005;129(3):322-32.
2004: Andrew J Davies; Ama Z S Rohatiner; S Howell; Keith E Britton; S E Owens; Ivana N M Micallef; David P Deakin; Bernadette M Carrington; J A L Lawrance; Sarah Vinnicombe; S J Mather; J Clayton; R Foley; HA Jan; Stewart Kroll; M Harris; John A Amess; Andrew J Norton; T Andrew Lister; John A Radford
Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(8):1469-79.
2004: M A Harris; John A Radford; David P Deakin; RD James; Ric Swindell; Richard A Cowan
Limited field radiotherapy for early stage, infra-diaphragmatic Hodgkin's lymphoma.
Clinical oncology (Royal College of Radiologists (Great Britain)) 2004;16(1):53-7.
2003: Deborah J Shears; Volker Endris; David A Gokhale; Simon P Dearden; John A Radford; Gudrun A Rappold; G Malcolm Taylor
Pseudoautosomal linkage of familial Hodgkin's lymphoma: molecular analysis of a unique family with Leri-Weill dyschondrosteosis and Hodgkins lymphoma.
British journal of haematology 2003;121(2):377-9.
2002: Simon J Howell; Mark Grey; James Chang; Godfrey R Morgenstern; Richard A Cowan; David P Deakin; John A Radford
The value of bone marrow examination in the staging of Hodgkin's lymphoma: a review of 955 cases seen in a regional cancer centre.
British journal of haematology 2002;119(2):408-11.
2002: Fiona H Blackhall; A D Atkinson; M B Maaya; W D J Ryder; Greg Horne; Daniel R Brison; Brian A Lieberman; John A Radford
Semen cryopreservation, utilisation and reproductive outcome in men treated for Hodgkin's disease.
British journal of cancer 2002;87(4):381-4.
2002: John A Radford; Ama Z S Rohatiner; W D J Ryder; David P Deakin; T Barbui; N P Lucie; A Rossi; D J Dunlop; Richard A Cowan; Peter M Wilkinson; R K Gupta; RD James; J Shamash; James Chang; Derek Crowther; T Andrew Lister
ChlVPP/EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin's disease.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(13):2988-94.
2001: Simon J Howell; John A Radford; Judith E Adams; E M Smets; R Warburton; Stephen M Shalet
Randomized placebo-controlled trial of testosterone replacement in men with mild Leydig cell insufficiency following cytotoxic chemotherapy.
Clinical endocrinology 2001;55(3):315-24.
2001: Ian Judson; John A Radford; M Harris; Jean-Yves Blay; Q G C M van Hoesel; Axel Le Cesne; Allan T van Oosterom; M J Clemons; Claus Kamby; C Hermans; J Whittaker; Eugenio Donato di Paola; Jaap Verweij; S Nielsen
Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group.
European journal of cancer (Oxford, England : 1990) 2001;37(7):870-7.
2001: John A Radford; Brian A Lieberman; Daniel R Brison; A R Smith; JD Critchlow; S A Russell; A J Watson; J A Clayton; M Harris; Roger G Gosden; S M Shalet
Orthotopic reimplantation of cryopreserved ovarian cortical strips after high-dose chemotherapy for Hodgkin's lymphoma.
Lancet 2001;357(9263):1172-5.
2001: Fiona H Blackhall; Malcolm Ranson; John A Radford; B W Hancock; M Soukop; Alan T McGown; A Robbins; Gavin Halbert; Gordon C Jayson
A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma.
British journal of cancer 2001;84(4):465-9.
2000: CR Crawley; JM Foran; RK Gupta; Ama Z S Rohatiner; Karin E Summers; Janet Matthews; Ivana N M Micallef; John A Radford; stephen johnson; Peter WM Johnson; J W Sweetenham; T Andrew Lister
A phase II study to evaluate the combination of fludarabine, mitoxantrone and dexamethasone (FMD) in patients with follicular lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(7):861-5.
2000: J Shamash; S M Lee; John A Radford; Ama Z S Rohatiner; J Chang; Godfrey R Morgenstern; John Howard Scarffe; David P Deakin; T Andrew Lister
Patterns of relapse and subsequent management following high-dose chemotherapy with autologous haematopoietic support in relapsed or refractory Hodgkin's lymphoma: a two centre study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(6):715-9.
2000: Simon J Howell; John A Radford; Judith E Adams; Stephen M Shalet
The impact of mild Leydig cell dysfunction following cytotoxic chemotherapy on bone mineral density (BMD) and body composition.
Clinical endocrinology 2000;52(5):609-16.
2000: Julie M Vose; Richard L Wahl; M Saleh; Ama Z S Rohatiner; Susan J Knox; John A Radford; Andrew D Zelenetz; George Tidmarsh; RJ Stagg; Mark S Kaminski
Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(6):1316-23.
2000: Simon J Howell; John A Radford; E M Smets; Stephen M Shalet
Fatigue, sexual function and mood following treatment for haematological malignancy: the impact of mild Leydig cell dysfunction.
British journal of cancer 2000;82(4):789-93.
2000: John A Radford
Is prevention of sterility possible in men?
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11 Suppl 3():173-4.
2000: James P Wylie; Richard A Cowan; John A Radford; David P Deakin; M Harris; Peter M Wilkinson
A doxorubicin-based regimen used in the treatment of elderly patients with high-grade non-Hodgkin's lymphoma.
Clinical oncology (Royal College of Radiologists (Great Britain)) 2000;12(3):153-7.
2000: Ole Steen Nielsen; Ian Judson; Q G C M van Hoesel; Axel Le Cesne; HJ Keizer; Jean-Yves Blay; Allan van Oosterom; John A Radford; L Svancárová; K Krzemienlecki; C Hermans; Martine Van Glabbeke; J W Oosterhuis; Jaap Verweij
Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group.
European journal of cancer (Oxford, England : 1990) 2000;36(1):61-7.
2000: JM Foran; Ama Z S Rohatiner; David Cunningham; R A Popescu; Philippe Solal-Celigny; M Ghielmini; Bertrand Coiffier; Peter WM Johnson; Christian Gisselbrecht; Felix Reyes; John A Radford; E M Bessell; B Souleau; A Benzohra; T Andrew Lister
European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(2):317-24.
1999: A J Bradley; Bernadette M Carrington; J A L Lawrance; W D J Ryder; John A Radford
Assessment and significance of mediastinal bulk in Hodgkin's disease: comparison between computed tomography and chest radiography.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(8):2493-8.
1999: SM Lee; W D J Ryder; Mark Clemons; Godfrey R Morgenstern; James Chang; John Howard Scarffe; John A Radford
Treatment outcome and prognostic factors for relapse after high-dose chemotherapy and peripheral blood stem cell rescue for patients with poor risk high grade non-Hodgkin's lymphoma.
Bone marrow transplantation 1999;24(3):271-7.
1999: G Malcolm Taylor; David A Gokhale; Derek Crowther; Penella J Woll; M Harris; D Ryder; Michelle Ayres; John A Radford
Further investigation of the role of HLA-DPB1 in adult Hodgkin's disease (HD) suggests an influence on susceptibility to different HD subtypes.
British journal of cancer 1999;80(9):1405-11.
1999: PS Sengupta; Gordon C Jayson; Richard J Slade; A Eardley; John A Radford
An audit of primary surgical treatment for women with ovarian cancer referred to a cancer centre.
British journal of cancer 1999;80(3-4):444-7.
1999: Simon J Howell; John A Radford; W D J Ryder; Stephen M Shalet
Testicular function after cytotoxic chemotherapy: evidence of Leydig cell insufficiency.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(5):1493-8.
1999: JM Foran; Ama Z S Rohatiner; Bertrand Coiffier; T Barbui; stephen johnson; W Hiddemann; John A Radford; Andrew J Norton; SM Tollerfield; M P Wilson; T Andrew Lister
Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenström's macroglobulinemia, and mantle-cell lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(2):546-53.
1998: M Adams; A H Calvert; J Carmichael; PI Clark; R E Coleman; Helena Earl; CJ Gallagher; Trivadi Ganesan; Martin E Gore; J D Graham; P G Harper; Gordon C Jayson; Stanley B Kaye; JA Ledermann; R J Osborne; Timothy J Perren; Christopher J Poole; John A Radford; Gordon J S Rustin; Maurice L Slevin; J F Smyth; H Thomas; Peter M Wilkinson
Chemotherapy for ovarian cancer--a consensus statement on standard practice.
British journal of cancer 1998;78(11):1404-6.
1998: Bertrand Coiffier; C Haioun; N Ketterer; Andreas Engert; Hervé Tilly; D Ma; P Johnson; Andrew Lister; M Feuring-Buske; John A Radford; R Capdeville; Volker Diehl; F Reyes
Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.
Blood 1998;92(6):1927-32.
1998: A Weaver; James Chang; E Wrigley; Erika A de Wynter; Penella J Woll; M Lind; B Jenkins; C Gill; Peter M Wilkinson; R Pettengell; John A Radford; Conor D Collins; TM Dexter; Nydia G Testa; Derek Crowther
Randomized comparison of progenitor-cell mobilization using chemotherapy, stem-cell factor, and filgrastim or chemotherapy plus filgrastim alone in patients with ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(8):2601-12.
1998: SM Lee; John A Radford; L Dobson; T Huq; W D J Ryder; R Pettengell; Godfrey R Morgenstern; John Howard Scarffe; Derek Crowther
Recombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgkin's lymphoma: clinical benefits at no extra cost.
British journal of cancer 1998;77(8):1294-9.
1997: MJ Dobson; Bernadette M Carrington; John A Radford; C H Buckley; Derek Crowther
The role of computed tomography in the management of ovarian tumours of borderline malignancy.
Clinical radiology 1997;52(4):280-3.
1997: John A Radford; A Eardley; C Woodman; Derek Crowther
Follow up policy after treatment for Hodgkin's disease: too many clinic visits and routine tests? A review of hospital records.
BMJ (Clinical research ed.) 1997;314(7077):343-6.
1997: SM Lee; John A Radford; W D J Ryder; Conor D Collins; David P Deakin; Derek Crowther
Prognostic factors for disease progression in advanced Hodgkin's disease: an analysis of patients aged under 60 years showing no progression in the first 6 months after starting primary chemotherapy.
British journal of cancer 1997;75(1):110-5.
1996: E Wrigley; A Weaver; Gordon C Jayson; Malcolm Ranson; J Renninson; J Prendiville; M Dobson; Conor D Collins; Ric Swindell; C H Buckley; John A Radford; Derek Crowther
A randomised trial investigating the dose intensity of primary chemotherapy in patients with ovarian carcinoma: a comparison of chemotherapy given every four weeks with the same chemotherapy given at three week intervals.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(7):705-11.
1996: R Pettengell; John A Radford; Godfrey R Morgenstern; John Howard Scarffe; M Harris; Penella J Woll; David P Deakin; D Ryder; Peter M Wilkinson; Derek Crowther
Survival benefit from high-dose therapy with autologous blood progenitor-cell transplantation in poor-prognosis non-Hodgkin's lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(2):586-92.
1995: John A Radford; Derek Crowther; Ama Z S Rohatiner; W D J Ryder; R K Gupta; Amit Oza; David P Deakin; S Arnott; Peter M Wilkinson; R D James
Results of a randomized trial comparing MVPP chemotherapy with a hybrid regimen, ChlVPP/EVA, in the initial treatment of Hodgkin's disease.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(9):2379-85.
1995: C Scheid; R Pettengell; M Ghielmini; John A Radford; Godfrey R Morgenstern; Peter L Stern; Derek Crowther
Time-course of the recovery of cellular immune function after high-dose chemotherapy and peripheral blood progenitor cell transplantation for high-grade non-Hodgkin's lymphoma.
Bone marrow transplantation 1995;15(6):901-6.
1995: Jade J Wong-You-Cheong; John A Radford
Case report: enlargement of a mediastinal mass during treatment for Hodgkin's disease may be due to accumulation of fluid within thymic cysts.
Clinical radiology 1995;50(1):61-2.
1995: S T Clark; John A Radford; Derek Crowther; Ric Swindell; Stephen M Shalet
Gonadal function following chemotherapy for Hodgkin's disease: a comparative study of MVPP and a seven-drug hybrid regimen.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(1):134-9.
1994: John A Radford; J S Whelan; Ama Z S Rohatiner; David P Deakin; M Harris; A G Stansfeld; Ric Swindell; Peter M Wilkinson; R D James; T Andrew Lister
Weekly VAPEC-B chemotherapy for high grade non-Hodgkin's lymphoma: results of treatment in 184 patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(2):147-51.
1994: John A Radford; S Clark; Derek Crowther; S M Shalet
Male fertility after VAPEC-B chemotherapy for Hodgkin's disease and non-Hodgkin's lymphoma.
British journal of cancer 1994;69(2):379-81.
1993: R Pettengell; Godfrey R Morgenstern; Penella J Woll; James Chang; M Rowlands; R Young; John A Radford; John Howard Scarffe; Nydia G Testa; Derek Crowther
Peripheral blood progenitor cell transplantation in lymphoma and leukemia using a single apheresis.
Blood 1993;82(12):3770-7.
1993: M E Van Hoef; John A Radford; A Jones; I E Smith; Helena Earl; Penella J Woll; Nick Thatcher
Urinary-derived monocyte-colony stimulating factor (P-100) following treatment with carboplatin and etoposide in small cell lung cancer (SCLC).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1993;4(10):877-81.
1993: Heather Anderson; P Hopwood; J Prendiville; John A Radford; Nick Thatcher; L Ashcroft
A randomised study of bolus vs continuous pump infusion of ifosfamide and doxorubicin with oral etoposide for small cell lung cancer.
British journal of cancer 1993;67(6):1385-90.
1993: John A Radford; Godfrey R Morgenstern; Derek Crowther
The management of Hodgkin's disease.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1993;4(5):417-21.
1992: R Pettengell; H Gurney; John A Radford; David P Deakin; R James; Peter M Wilkinson; Kevin Kane; J Bentley; Derek Crowther
Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial.
Blood 1992;80(6):1430-6.
1992: John A Radford; W D J Ryder; D Dodwell; Heather Anderson; Nick Thatcher
Predicting septic complications of chemotherapy: an analysis of 382 patients treated for small cell lung cancer without dose reduction after major sepsis.
European journal of cancer (Oxford, England : 1990) 1992;29A(1):81-6.
1991: John A Radford; Derek Crowther
Treatment of relapsed Hodgkin's disease using a weekly chemotherapy of short duration: results of a pilot study in 20 patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1991;2(7):505-9.
1991: Malcolm Ranson; John A Radford; Ric Swindell; David P Deakin; Peter M Wilkinson; M Harris; R J Johnson; Derek Crowther
An analysis of prognostic factors in stage III and IV Hodgkin's disease treated at a single centre with MVPP.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1991;2(6):423-9.
1991: Heather Anderson; Derek Crowther; David P Deakin; W D J Ryder; John A Radford
A randomised study of adjuvant MVPP chemotherapy after mantle radiotherapy in pathologically staged IA-IIB Hodgkin's disease: 10-year follow-up.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1991;2 Suppl 2():49-54.
1991: John A Radford; J M Margison; Ric Swindell; Michael Lind; Peter M Wilkinson; Nick Thatcher
The stability of ifosfamide in aqueous solution and its suitability for continuous 7-day infusion by ambulatory pump.
Journal of cancer research and clinical oncology 1991;117 Suppl 4():S154-6.
1991: Heather Anderson; J Prendiville; Nick Thatcher; John A Radford; Ric Swindell
A randomised study of intravenous bolus versus continuous infusion of ifosfamide and doxorubicin with oral etoposide for small-cell lung cancer.
Journal of cancer research and clinical oncology 1991;117 Suppl 4():S139-40.
1990: John A Radford; Nydia G Testa; Derek Crowther
The long-term effects of MVPP chemotherapy for Hodgkin's disease on bone marrow function.
British journal of cancer 1990;62(1):127-32.
1990: W P Steward; John Howard Scarffe; L Y Dirix; J Chang; John A Radford; E Bonnem; Derek Crowther
Granulocyte-macrophage colony stimulating factor (GM-CSF) after high-dose melphalan in patients with advanced colon cancer.
British journal of cancer 1990;61(5):749-54.
1990: John A Radford; J M Margison; Ric Swindell; Michael Lind; Peter M Wilkinson; Nick Thatcher
The stability of ifosfamide in aqueous solution and its suitability for continuous 7-day infusion by ambulatory pump.
Cancer chemotherapy and pharmacology 1990;26(2):144-6.
1989: Richard A Cowan; M Jones; M Harris; W P Steward; John A Radford; John Wagstaff; David P Deakin; Derek Crowther
Prognostic factors in high and intermediate grade non-Hodgkin's lymphoma.
British journal of cancer 1989;59(2):276-82.
1988: John A Radford; Richard A Cowan; M Flanagan; G Dunn; Derek Crowther; R J Johnson; B Eddleston
The significance of residual mediastinal abnormality on the chest radiograph following treatment for Hodgkin's disease.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(6):940-6.